Defibrillator Manufacturing in European Union: Market Size, Businesses & Forecast 2026

The defibrillator manufacturing industry in the European Union is a highly specialized sector dedicated to producing automated external defibrillators (AEDs), implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy devices. The industry is currently expanding to address the critical public health challenge of cardiovascular diseases, which claim 1.7 million lives every year in the EU according to the European Commission Safe Hearts Plan in 2025. Manufacturing and deployment are shifting toward smart, connected, and remote-monitored equipment to reduce hospital burdens, while adapting to strict regulatory standards that have altered structural market entry.

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Defibrillator Manufacturing in European Union industry cover?

This industry encompasses the development, design, and manufacturing of medical devices that deliver electrical shocks to restore normal heart rhythms during sudden cardiac arrest or life-threatening arrhythmias. Under European classification systems, this includes external portable systems used by bystanders and medical personnel, as well as highly complex active implantable electronic devices.

• •Covers Automated External Defibrillators (AEDs) designed for public access and emergency response deployment.
• •Includes Active Implantable Medical Devices (AIMDs) like Implantable Cardioverter-Defibrillators (ICDs).
• •Encompasses Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) that manage advanced heart failure.

Who operates in the industry and how is it structured?

The market structure is characterized by a high degree of consolidation among major global medical technology firms alongside specialized European engineering firms. Operators are primarily multinational enterprises capable of sustaining long product development cycles and extensive clinical trials required to clear rigid European market access hurdles.

• •Highly consolidated structure due to advanced technological barriers and extensive R&D capital requirements.
• •Production is distributed across advanced manufacturing hubs in western and central Europe.
• •Operators heavily rely on authorized notified bodies for product conformity assessments across the EU.

What drives demand in the industry?

The primary demand driver is the significant clinical and economic burden of cardiovascular diseases, which cost the European economy over EUR 282 billion per year as of 2025. Public health initiatives to increase the density of public-access AEDs in municipalities and workplaces also drive sustained volume growth.

• •Cardiovascular diseases represent the leading cause of death and disability across the EU.
• •Decentralized public deployment campaigns by regional governments and corporate safety mandates.
• •An aging European demographic naturally increases the clinical incidence of complex cardiac arrhythmias.

Who are the notable companies in the industry?

The competitive ecosystem features prominent global conglomerates with deep roots in European manufacturing, alongside key domestic medical electronics leaders. Competition is driven by engineering innovations such as battery longevity, device miniaturization, and seamless magnetic resonance imaging (MRI) compatibility.

• •Koninklijke Philips N.V. is a primary public entity in the external and automated defibrillator space.
• •Biotronik SE & Co. KG operates as a prominent European manufacturer specializing in advanced implantable ICD systems.
• •Medtronic plc and Boston Scientific Corporation maintain significant manufacturing, R&D, and corporate operations inside the EU.
• •Schiller AG and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. are major players supplying public-access AED apparatus to the European market.

What are the recent trends and outlook?

Recent innovations are heavily centered on integrating remote monitoring (RM) capabilities and digital health software into defibrillator infrastructure. This transition enables clinical teams to track patient device telemetry remotely, which minimizes in-clinic patient traffic and improves early detection metrics.

• •Widespread integration of artificial intelligence and machine learning for predictive arrhythmia detection.
• •Development of ultra-slim, body-friendly device shapes to lower post-implantation skin erosion risks.
• •Expansion of remote monitoring systems to mitigate geographical and healthcare delivery disparities.

How is the industry regulated?

The industry is rigidly governed by the European Union Medical Device Regulation (MDR), which replaced the legacy Active Implantable Medical Device Directive. The regulation enforces strict clinical data requirements, enhanced traceability, and comprehensive post-market surveillance protocols.

• •MDR compliance has driven up administrative, testing, and implementation costs for medical technology operators.
• •Transition periods for compliance have been extended out to 2027 or 2028 depending on device risk class profiles.
• •Regulatory barriers have contributed to selective product portfolio rationalization and niche market withdrawals.

Government, statistical and trade sources used for this Claight analysis.

• European Commission Safe Hearts Plan 2025 ·
• MedTech Europe Cardiac Rhythm Management Statistics ·
• Eurostat Health Statistics ·
• European Heart Rhythm Association (EHRA) Patient Survey